KRAS and pancreatic neoplasm: Interestingly, RNF43 mutations in pancreatic cancer shift the pancreatic cancer dependency to WNT signaling rather than oncogenic KRAS [137], further underscoring the importance of this E3 ligase as a negative regulator of WNT signaling and a tumor suppressor.